Menu Search
Equities

Astellas Pharma Inc

4503:TYO

Astellas Pharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,544.50
  • Today's Change-18.00 / -1.15%
  • Shares traded7.33m
  • 1 Year change-25.35%
  • Beta0.7073
Data delayed at least 20 minutes, as of May 08 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 06-May-24
Select bar for recommendation details.
Recommendations06-May-24
Buy2
Outperform7
Hold6
Underperform1
Sell0

Share price forecast in JPY

The 14 analysts offering 12 month price targets for Astellas Pharma Inc have a median target of 2,025.00, with a high estimate of 3,170.00 and a low estimate of 1,200.00. The median estimate represents a 31.11% increase from the last price of 1,544.50.
High105.2%3,170.00
Med31.1%2,025.00
Low-22.3%1,200.00

Dividends in JPY

In 2024, Astellas Pharma Inc reported a dividend of 70.00 JPY, which represents a 16.67% increase over last year. The 13 analysts covering the company expect dividends of 74.62 JPY for the upcoming fiscal year, an increase of 6.59%.
Div growth (TTM)16.67%
More ▼

Earnings history & estimates in JPY

On Apr 25, 2024, Astellas Pharma Inc reported 4th quarter 2024 losses of -18.55 per share.
The next earnings announcement is expected on Jul 30, 2024.
Astellas Pharma Inc reported annual 2024 earnings of 9.51 per share on Apr 25, 2024.
Average growth rate-33.99%
More ▼

Revenue history & estimates in JPY

Astellas Pharma Inc. had 4th quarter 2024 revenues of 414.60m. This bettered the 379.51m consensus of the 7 analysts covering the company. This was 8.59% above the prior year's 4th quarter results.
Average growth rate+4.07%
Astellas Pharma Inc. had revenues for the full year 2024 of 1.60bn. This was 5.60% above the prior year's results.
Average growth rate+5.64%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.